Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, November 20, 2017
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Monday, November 6, 2017
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
Tuesday, October 31, 2017
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
Tuesday, October 24, 2017
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
Friday, October 13, 2017
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
Wednesday, October 11, 2017
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Wednesday, October 4, 2017
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
Tuesday, October 3, 2017
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: